{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:53:06Z","timestamp":1780487586546,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen US Medical Affairs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11523-022-00932-8","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:02:39Z","timestamp":1670310159000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8362-7068","authenticated-orcid":false,"given":"Gordon","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Belkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Hafron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Saltzstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushikesh","family":"Potdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabha","family":"Bhaumik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"932_CR1","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel DA, O'Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race\/ethnicity\u2014United States, 2001\u20132017. MMWR Morb Mortal Wkly Rep. 2020;69:1473\u201380. https:\/\/doi.org\/10.15585\/mmwr.mm6941a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"932_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/bju.13537","volume":"119","author":"A Winter","year":"2017","unstructured":"Winter A, Sirri E, Jansen L, Wawroschek F, Kieschke J, Castro FA, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? BJU Int. 2017;119:550\u20139. https:\/\/doi.org\/10.1111\/bju.13537.","journal-title":"BJU Int"},{"key":"932_CR3","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","volume":"28","author":"MR Cooperberg","year":"2010","unstructured":"Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117\u201323. https:\/\/doi.org\/10.1200\/JCO.2009.26.0133.","journal-title":"J Clin Oncol"},{"key":"932_CR4","first-page":"219","volume":"1","author":"A D'Amico","year":"1993","unstructured":"D\u2019Amico A, Altschuler M, Whittington R, Kao G, Malkowicz SB, Wein A. The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care. 1993;1:219\u201322.","journal-title":"Clin Perform Qual Health Care"},{"key":"932_CR5","unstructured":"National Comprehensive Cancer Network. Prostate cancer. Version 4.2022-May 10, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 12 Aug 2022."},{"key":"932_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","volume":"7","author":"EM Messing","year":"2006","unstructured":"Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(06)70700-8.","journal-title":"Lancet Oncol"},{"key":"932_CR7","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591\u20137. https:\/\/doi.org\/10.1001\/jama.281.17.1591.","journal-title":"JAMA"},{"key":"932_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JU.0000000000001702","volume":"206","author":"RR McKay","year":"2021","unstructured":"McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, et al. Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer. J Urol. 2021;206:80\u20137. https:\/\/doi.org\/10.1097\/JU.0000000000001702.","journal-title":"J Urol"},{"key":"932_CR9","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72:1494\u2013503. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3948.","journal-title":"Cancer Res"},{"key":"932_CR10","unstructured":"ERLEADA\u00ae (apalutamide) [Prescribing information]. Horsham: Janssen Pharmaceutical Companies; 2019."},{"issue":"Suppl 6","key":"932_CR11","doi-asserted-by":"publisher","first-page":"TPS285","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS285","volume":"40","author":"AS Kibel","year":"2022","unstructured":"Kibel AS, Gleave M, Brookman-May SD, Kim W, Evans CP, Efstathiou E, et al. PROTEUS: a randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC). J Clin Oncol. 2022;40(Suppl 6):TPS285. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS285.","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"932_CR12","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1200\/JCO.2022.40.16_suppl.5084","volume":"40","author":"HM Sandler","year":"2022","unstructured":"Sandler HM, Freedland SJ, Shore ND, Smith MR, Rosales RS, Brookman-May SD, et al. Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC). J Clin Oncol. 2022;40(Suppl 16):5084. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5084.","journal-title":"J Clin Oncol"},{"key":"932_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"DP Dearnaley","year":"2020","unstructured":"Dearnaley DP, Saltzstein DR, Sylvester JE, Karsh L, Mehlhaff BA, Pieczonka C, et al. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial. Eur Urol. 2020;78:184\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.001.","journal-title":"Eur Urol"},{"key":"932_CR14","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1210\/jc.2015-2770","volume":"100","author":"DB MacLean","year":"2015","unstructured":"MacLean DB, Shi H, Faessel HM, Saad F. Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab. 2015;100:4579\u201387. https:\/\/doi.org\/10.1210\/jc.2015-2770.","journal-title":"J Clin Endocrinol Metab"},{"key":"932_CR15","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1002\/cam4.2442","volume":"8","author":"H Suzuki","year":"2019","unstructured":"Suzuki H, Uemura H, Mizokami A, Hayashi N, Miyoshi Y, Nagamori S, et al. Phase I trial of TAK-385 in hormone treatment-naive Japanese patients with nonmetastatic prostate cancer. Cancer Med. 2019;8:5891\u2013902. https:\/\/doi.org\/10.1002\/cam4.2442.","journal-title":"Cancer Med"},{"key":"932_CR16","unstructured":"ORGOVYX (relugolix) [Prescribing information]. Brisbane: Myovant Sciences, Inc.; 2020."},{"issue":"Suppl 6","key":"932_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS207","volume":"40","author":"J De La Cerda","year":"2022","unstructured":"De La Cerda J, Migoya E, Brown B, Lu S, Zohren F, Tutrone RF, et al. Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): a phase 1, three-part, open-label, parallel-cohort study. J Clin Oncol. 2022;40(Suppl 6):207. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS207.","journal-title":"J Clin Oncol"},{"key":"932_CR18","unstructured":"Hafron JM, Saltzstein DR, Lacouture ME, Sutton J, Potdar R, Bhaumik A, et al. Society of Urologic Oncology 22nd Annual Meeting. Apa-RP: phase 2 study of apalutamide and androgen-deprivation therapy (ADT) in treatment-naive patients post-radical prostatectomy (RP) for nonmetastatic prostate cancer at high risk for metastases; 2021. https:\/\/suo-abstracts.secure-platform.com\/a\/gallery\/rounds\/12\/details\/1524. Accessed 17 Jun 2022."},{"key":"932_CR19","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382:2187\u201396. https:\/\/doi.org\/10.1056\/NEJMoa2004325.","journal-title":"N Engl J Med"},{"key":"932_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307.","journal-title":"N Engl J Med"},{"key":"932_CR21","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39:2294\u2013303. https:\/\/doi.org\/10.1200\/JCO.20.03488.","journal-title":"J Clin Oncol"},{"key":"932_CR22","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1715546.","journal-title":"N Engl J Med"},{"key":"932_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.011.","journal-title":"Eur Urol"},{"key":"932_CR24","unstructured":"ClinicalTrials.gov. Study of relugolix in men with metastatic castration-sensitive prostate cancer or non-metastatic or metastatic castration-resistant prostate cancer; 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04666129. Accessed 20 Jun 2022."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00932-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-022-00932-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00932-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T06:33:35Z","timestamp":1676615615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-022-00932-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1007\/s11523-022-00932-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"2 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Janssen US Medical Affairs. The sponsor was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation and review of the manuscript. The sponsor paid the open access fee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gordon Brown: Consultant\/advisor, speakers\u2019 bureau, expert testimony: Astellas Pharma, Bayer, Janssen, Merck, and Pfizer; research funding: Janssen Biotech, Merck. Jason M. Hafron: Consultant\/advisor: Astellas Pharma Inc., Dendreon Pharmaceuticals LLC, Janssen Biotech Inc., Myriad Genetic Laboratories, Myovant Sciences, Pfizer Inc., Promaxo, Lynx DX; meeting participant\/lecturer: Astellas Pharma Inc., Amgen Inc., Bayer, Blue Earth Diagnostics, Dendreon Pharmaceuticals LLC, Janssen Biotech Inc., Lantheus, Merck & Co., Myriad Genetic Laboratories, Myovant Sciences, Pfizer Inc., Procept-Biorobotic, Progenics Pharmaceuticals, Inc., Tolmar Pharmaceuticals Inc., Urogen Pharma Inc. Neal D. Shore: Consultant\/advisor: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Boston Scientific, Bristol-Myers Squibb\/Sanofi, Clarity Pharmaceuticals, CG Oncology, Clovis Oncology, Dendreon, Exact Imaging, Exact Sciences, FerGene, Ferring, Foundation Medicine, Genesis Cancer Care, Genzyme, InVitae, Janssen Scientific Affairs, Lantheus, Lilly, MDxHealth, Medivation\/Astellas, Merck, Myovant Sciences, Myriad Genetics, Nymox, Pacific Edge Biotechnology, Pfizer, Phosphorus, Sanofi, Sema4, Sesen Bio, Specialty Networks, Peerview, Photocure, Propella Therapeutics, Telix Pharmaceuticals, Tempus, Tolmar, Urogen Pharma, Vaxiion; speakers\u2019 bureau: Astellas Pharma, AstraZeneca, Bayer, Janssen, Clovis Oncology, Foundation Medicine, Guardant Health, Merck, Pfizer; expert testimony: Ferring; research finding: AbbVie, Advantagene, Amgen, Aragon Pharmaceuticals, Astellas Pharma, AstraZeneca, Bayer, Boston Scientific, Bristol-Myers Squibb\/Pfizer, CG Oncology, Clovis Oncology, Dendreon, DisperSol, Endocyte, Exact Imaging, Exelixis, Ferring, FKD Therapies, FORMA Therapeutics, Foundation Medicine, Genentech, Guardant Health, InVitae, ISTARI Oncology, Janssen, Jiangsu Yahong Meditech, MDxHealth, Medivation, Merck, MT Group, Myovant Sciences, Myriad Genetics, Novartis, Nymox, OncoCellMDx, Pacific Edge, Palette Life Sciences, Pfizer, Plexxikon, POINT Biopharma, Propella Therapeutics, RhoVac, Sanofi, Seattle Genetics, Sesen Bio, Steba Biotech, Theralase, Tolmar, Very, Urogen Pharma, Urotronic, US Biotest, Vaxiion, Zenflow. Rushikesh Potdar, Amitabha Bhaumik, Jennifer Phillips, and Tracy McGowan are employees of Janssen US Medical Affairs or Janssen Research & Development and may hold stock in Johnson & Johnson. Laurence Belkoff and Daniel R. Saltzstein have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at . As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Independent Ethics Committees or Institutional Review Boards at all participating institutions approved the Apa-RP study, which was conducted in accordance with International Council for Harmonisation guidelines for Good Clinical Practice and according to the principles of the Declaration of Helsinki.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Informed consent was obtained from all individual participants included in the study. No patient-identifying information is included in this article; therefore, consent to publish was not required.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"All authors participated in the design and conduct of the study, had access to the data, drafted the manuscript with input from the sponsor (Janssen), reviewed and approved the manuscript before submission, made the decision to submit the manuscript for publication, and agreed to be accountable for all aspects of this work. Gordon Brown had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}